Timberlyne Therapeutics key facts
as of Oct 2026- Operator of a biopharmaceutical company intended to develop and commercialize therapies for autoimmune diseases.
- Timberlyne Therapeutics is valued at approximately $324.2M as of Oct 2026 (last reported valuation).
- It has raised $180.0M; the latest was Early Stage VC ($180.0M) in Jan 2025.
- Notable investors include Venrock, Boyu Capital, Bain Capital Life Sciences, Braidwell, 3H Health Investment — 7 tracked in total.
- Status: Privately Held (backing).
Timberlyne Therapeutics's last reported valuation, Jan 2025. Nothing priced has surfaced since.
- ·Watch Timberlyne Therapeutics: the Monday email on marks, rounds and moves
Timberlyne Therapeutics funding rounds
No funding rounds for Timberlyne Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Timberlyne Therapeutics
7Timberlyne Therapeutics valuation
Timberlyne Therapeutics's last reported valuation was $324 million in Jan 2025. No priced round, secondary trade or fund mark has surfaced since.
Timberlyne Therapeutics investors
7 investors are on record for Timberlyne Therapeutics, including Venrock, Boyu Capital, Bain Capital Life Sciences and Braidwell.
About Timberlyne Therapeutics
Operator of a biopharmaceutical company intended to develop and commercialize therapies for autoimmune diseases. The company specializes in monoclonal antibodies with enhanced complement-dependent cytotoxicity that target CD38, which is highly expressed in plasma cells, NK cells, and other immune cells and can modulate multiple arms of the immune system, enabling medical companies to access both rapid and durable responses across a range of autoimmune diseases.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2024
- Employees
- 13
- Website
- timberlyne-tx.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.